Table 1 Patient demographics and clinical characteristics.
Characteristics | Total (N = 29) No. of patients (%) |
|---|---|
Age at enrollment, years | |
Median [range] | 57 [39-76] |
Gender | |
Male | 14 (48.3) |
Female | 15 (51.7) |
Treatment line at the time of sampling | |
FOLFIRI + bevacizumab | 15 (51.7) |
FOLFIRI + ramucirumab | 10 (34.5) |
FOLFOX + bevacizumab | 4 (13.8) |
Primary site | |
Right-sided colon | 13 (44.8) |
Left-sided colon | 16 (55.2) |
Resection of primary tumor | |
Yes | 18 (62.1) |
No | 11 (37.9) |
Metastatic site | |
Single organ | 8 (27.6) |
Multi-organ | 21 (72.4) |
Liver | 27 (93.1) |
Lung | 14 (48.3) |
Peritoneal | 9 (31.0) |
Lymph node | 7 (24.1) |
Other | 3 (10.3) |
RAS status in tissue | |
Wild type | 10 (34.5) |
Mutant | 19 (65.5) |
Prior Chemotherapy regimen | |
Anti-VEGF antibody | 21 (72.4) |
Anti-EGFR antibody | 6 (20.7) |
Cytotoxic drug(s) only | 2 (6.9) |
Tumor markers (at initiation of second-line chemotherapy) | |
CEA median, [range] | 48.6 [3.4–1119.9] |
CA19-9 median, [range] | 62.1 [2.0–8017.7] |
